In clinical trials, CYTALUX detected additional ovarian cancer
which would have been left behind.
With CYTALUX, additional malignant lesions were found in 27% of patients.*
In a subgroup analysis of patients with confirmed FR+ ovarian cancer, all of whom underwent interval debulking surgery, additional malignant lesions were found in 40% of interval debulking patients.**
Surgeons indicated the use of CYTALUX altered their surgical plan in 54% of their cases.***
* Women highly suspicious for or with confirmed ovarian cancer who underwent both normal and fluorescent light evaluation (Intent-to-Image set); N=134, 95% CI [19.6, 35.2]
**Phase 3 (006 Study): N=134, 95% CI [19.6, 35.2]. Primary endpoint: Proportion of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology that was detected using the combination of CYTALUX and fluorescent light but not under normal light or palpation.
***Phase 3 (006 Study): Based on a prespecified exploratory endpoint for the proportion of subjects for whom the fluorescence surgical plan was changed based on fluorescence imaging both prior to initiation of the surgical procedure and upon re-imaging of the surgical field after surgical procedure prior to closing. (N=109, 95% CI [44.3,63.7])
Watch CYTALUX in Cytoreductive Surgery for Ovarian Cancer
Speak with a representative
about CYTALUX and how to bring this technology to your OR.